In general, expression of HCV proteins (e.g., core protein and/or non-structural protein 3 (NS3)) in non-hepatic tissues, activation of oncogenes through inhibition of DNA repair and tumor-suppressor genes, in addition to chronic inflammation, have been suggested as potential mechanisms through which HCV modulates extrahepatic cancer risk (38, 40). This evidence concerns the gene KRAS and neoplasm.